Live Breaking News & Updates on Preclinical Development At Bold Therapeutics

Stay updated with breaking news from Preclinical development at bold therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that. ....

San Diego , United States , South Korea , British Columbia , Soult Ukpyolsi , E Russell Mcallister , Jim Pankovich , Clinical Development At Bold Therapeutics , Bold Therapeutics Inc , Preclinical Development At Bold Therapeutics , Seoul National University College Of Medicine , Bold Therapeutics , Seoul National University College , Pancreatic Ductal Adenocarcinoma , Cellular Stress Responses , Pancreatic Ductal , Preclinical Development , Clinical Development , Mark Bazett , Bold Therapeutic ,

BOLD-100's Broad Potential Featured at the AACR Annual Meeting 2022

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in. ....

South Korea , British Columbia , Mark Bazett , Walter Berger , Preclinical Development At Bold Therapeutics , Bold Therapeutics Inc , University Of Vienna , Small Molecule Therapeutic Agents , Medical University , Anticancer Ruthenium Compound , Metabolic Vulnerability , Preclinical Development , Bold Therapeutics , Bold Therapeutics Inc ,

BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting

Queen s University Belfast, Northern Ireland
Van Schaeybroeck s AACR poster presentation Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen s University Belfast, which investigated BOLD-100 s mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF-mutant colorectal cancers.
Colon cancer is one of the most frequently diagnosed malignancies in adults, responsible for approximately 11% of all new cases of cancers worldwide and one-third of cancer deaths. BRAF-mutant colorectal cancers comprise 10% of those patients, and this subgroup has morphological, clinical, and therapeutic characteristics that differ substantially from patients without this genetic alteration. Importantly, there is no established standard of care for BRAF- ....

United States , United Kingdom , South Korea , British Columbia , Mark Bazett , E Russell Mcallister , Sandra Van Schaeybroeck , Van Schaeybroeck , Drug Resistance Group , Preclinical Development At Bold Therapeutics , Bold Therapeutics Inc , Phd Queen University Belfast , Bold Therapeutics , University Belfast , Cancer Research , Preclinical Development , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , தெற்கு கொரியா , பிரிட்டிஷ் கொலம்பியா , ஏ ரஸ்ஸல் மக்யாலிஸ்டர் , தைரியமான சிகிச்சை இன்க் , தைரியமான சிகிச்சை , பல்கலைக்கழகம் பெல்ஃபாஸ்ட் , புற்றுநோய் ஆராய்ச்சி ,